Literature DB >> 17695386

Chordomas of the skull base: surgical management and outcome.

Amir Samii1, Venelin M Gerganov, Christian Herold, Nakamasa Hayashi, Takahiko Naka, M Javad Mirzayan, Helmut Ostertag, Madjid Samii.   

Abstract

OBJECT: The goal of this study was to report on the surgical management of skull base chordomas and to evaluate both the short- and long-term treatment outcomes.
METHODS: The authors retrospectively studied data from 49 patients who had undergone consecutive surgeries at a single institution. They also analyzed patterns of chordoma extension. Complications and surgery-related morbidity were recorded. A Kaplan-Meier analysis was performed to determine survival rates in patients 5 and 10 years after their first surgery. Operative approaches were selected on the basis of the predominant tumor extension.
RESULTS: The approach used most frequently was the transethmoidal in 36.3%, followed by the pterional in 23.4% and the retrosigmoid in 23.4%. The tumor was totally removed in 49.4% and subtotally in 50.6%. The rate of total removal was highest at initial surgery (78%) and progressively declined thereafter. In 11.8% of cases a new neurological deficit developed, while the preoperative deficit remained unchanged. In 20% of cases the preoperative deficits improved, but new deficits also appeared. The 5- and 10-year survival rates are 65 and 39%, respectively.
CONCLUSIONS: With an individually tailored surgical approach, total tumor removal in 78% of the cases was achieved at the initial surgery. Radical surgery appears to increase slightly the surgical morbidity, but at the same time prolongs the recurrence-free interval. Chordomas cannot be regarded as surgically curable tumors given the 5- and 10-year survival rates in patients harboring such lesions.

Entities:  

Mesh:

Year:  2007        PMID: 17695386     DOI: 10.3171/JNS-07/08/0319

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  41 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  Recurrent chordoma with orbital and eyelid invasion.

Authors:  Yamini Krishna; Saad Qureshi; Austin McCormick; Sarah E Coupland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-29       Impact factor: 3.117

3.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

4.  Metastatic disease to the clivus mimicking clival chordomas.

Authors:  Adam S Deconde; Yas Sanaiha; Jeffrey D Suh; Sunita Bhuta; Marvin Bergsneider; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2013-06-26

Review 5.  Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients.

Authors:  Muneyoshi Yasuda; Damien Bresson; Salvatore Chibbaro; Jan F Cornelius; Marc Polivka; Loic Feuvret; Masakazu Takayasu; Bernard George
Journal:  Neurosurg Rev       Date:  2011-08-24       Impact factor: 3.042

6.  SNF5 as a prognostic factor in skull base chordoma.

Authors:  Mingxuan Li; Yixuan Zhai; Jiwei Bai; Shuai Wang; Hua Gao; Chuzhong Li; Songbai Gui; Jiang Du; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2017-12-08       Impact factor: 4.130

7.  A Parapharyngeal Soft Tissue Chordoma Presenting with Synchronous Cervical Lymph Node Metastasis: An Unusual Presentation.

Authors:  S A Khurram; D Biswas; M Fernando
Journal:  Head Neck Pathol       Date:  2016-03-16

8.  Endoscopic transnasal surgery of clival lesions: our experience.

Authors:  Daniele Marchioni; Angelo Musumeci; Cristoforo Fabbris; Stefano De Rossi; Davide Soloperto
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-08       Impact factor: 2.503

9.  Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study.

Authors:  Anna V Nikoghosyan; Irini Karapanagiotou-Schenkel; Marc W Münter; Alexandra D Jensen; Stephanie E Combs; Jürgen Debus
Journal:  BMC Cancer       Date:  2010-11-05       Impact factor: 4.430

10.  The role of Gamma Knife surgery in the treatment of skull base chordomas.

Authors:  Kasandra Dassoulas; David Schlesinger; Chun Po Yen; Jason Sheehan
Journal:  J Neurooncol       Date:  2009-03-11       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.